Dordaviprone
Based on 10 publication(s) in Google Scholar
Dordaviprone (TIC10) is a potent, orally active, and stable tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducer which acts by inhibiting Akt and ERK, consequently activating Foxo3a and significantly inducing cell surface TRAIL. Dordaviprone can cross the blood-brain barrier.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 1616632-77-9
- Formula: C24H26N4O
- Molecular Weight:386.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Dordaviprone
More- Cancer Cell. 2019 May 13;35(5):721-737.e9. [Abstract]
- Phytomedicine. 2024 Jan:122:155163. [Abstract]
- NPJ Precis Oncol. 2025 Nov 21;9(1):373. [Abstract]
- Cell Chem Biol. 2022 Sep 15;29(9):1396-1408.e8. [Abstract]
- Br J Cancer. 2023 Mar;128(7):1344-1359. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Biochem Biophys Res Commun. 2024 May 14:708:149802. [Abstract]
- University of Rijeka. 2023.
- Johannes Gutenberg University Mainz. 2021 Dec 17.
- Oncotarget. 2018 Jan 10;9(15):12020-12034. [Abstract]
-
WB
Biological Activity
|
TRAIL |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
3.24 μM
Compound: ONC201
|
Anticancer activity against human A-375 cells assessed as cell viability measured after 72 hrs by CCK-8 assay
Anticancer activity against human A-375 cells assessed as cell viability measured after 72 hrs by CCK-8 assay
|
[PMID: 40317731] |
| A549 | IC50 |
10.07 μM
Compound: ONC201
|
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| COLO 205 | IC50 |
15.1 μM
Compound: ONC201
|
Growth inhibition of human COLO205 cells after 3 days by WST8 assay
Growth inhibition of human COLO205 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| DLD-1 | IC50 |
5.46 μM
Compound: ONC201
|
Antiproliferative activity against human DLD-1 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human DLD-1 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| H9c2 | IC50 |
>50 μM
Compound: ONC201
|
Antiproliferative activity against rat H9c2 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against rat H9c2 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| HCT-116 | IC50 |
1.22 μM
Compound: ONC201
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis
|
[PMID: 35649291] |
| HCT-116 | IC50 |
4.06 μM
Compound: ONC201
|
Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| HCT-15 | IC50 |
10.1 μM
Compound: ONC201
|
Antiproliferative activity against human HCT-15 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human HCT-15 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| HEK293 | IC50 |
>50 μM
Compound: ONC201
|
Antiproliferative activity against human HEK293 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human HEK293 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| HEK-293T | IC50 |
1 μM
Compound: 8; ONC201
|
Cytotoxicity against HEK293-T-REx cells
Cytotoxicity against HEK293-T-REx cells
|
[PMID: 37974956] |
| HepG2 | IC50 |
9.8 μM
Compound: ONC201
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis
|
[PMID: 35649291] |
| HT-29 | IC50 |
35 μM
Compound: ONC201
|
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| KYSE-140 | IC50 |
58.1 μM
Compound: ONC201
|
Growth inhibition of human KYSE-140 cells after 3 days by WST8 assay
Growth inhibition of human KYSE-140 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| MDA-MB-231 | IC50 |
>20 μM
Compound: ONC201
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| MDA-MB-231 | IC50 |
10 μM
Compound: 70; ONC201, TIC10
|
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by CellTiter-Glo luminescent assay
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by CellTiter-Glo luminescent assay
|
[PMID: 33650861] |
| MDA-MB-231 | IC50 |
14.6 μM
Compound: ONC201
|
Growth inhibition of human MDA-MB-231 cells after 3 days by WST8 assay
Growth inhibition of human MDA-MB-231 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| MDA-MB-468 | IC50 |
8.9 μM
Compound: ONC201
|
Growth inhibition of human MDA-MB-468 cells after 3 days by WST8 assay
Growth inhibition of human MDA-MB-468 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| MOLM-13 | IC50 |
7.5 μM
Compound: ONC201
|
Growth inhibition of human MOLM13 cells after 3 days by WST8 assay
Growth inhibition of human MOLM13 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| MOLM-14 | IC50 |
6.3 μM
Compound: ONC201
|
Growth inhibition of human MOLM14 cells after 3 days by WST8 assay
Growth inhibition of human MOLM14 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| MV4-11 | IC50 |
3 μM
Compound: ONC201
|
Growth inhibition of human MV4-11 cells after 3 days by WST8 assay
Growth inhibition of human MV4-11 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| MV4-11 | IC50 |
3.25 μM
Compound: ONC201
|
Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis
Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis
|
[PMID: 35649291] |
| NCI-H3122 | IC50 |
8.7 μM
Compound: ONC201
|
Growth inhibition of human NCI-H3122 cells after 3 days by WST8 assay
Growth inhibition of human NCI-H3122 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| OCI-AML2 | IC50 |
2400 nM
Compound: 34; ONC201
|
Cytotoxicity against human OCI-AML2 cells assessed as cell growth inhibition measured after 72 hrs by spectrophotometry
Cytotoxicity against human OCI-AML2 cells assessed as cell growth inhibition measured after 72 hrs by spectrophotometry
|
[PMID: 33656892] |
| OCI-AML-3 | IC50 |
1.2 μM
Compound: 8; ONC201
|
Cytotoxicity against human OCI-AML-3 cells
Cytotoxicity against human OCI-AML-3 cells
|
[PMID: 37974956] |
| OCI-AML-3 | IC50 |
1200 nM
Compound: 34; ONC201
|
Cytotoxicity against human OCI-AML-3 cells assessed as cell growth inhibition measured after 72 hrs by spectrophotometry
Cytotoxicity against human OCI-AML-3 cells assessed as cell growth inhibition measured after 72 hrs by spectrophotometry
|
[PMID: 33656892] |
| PC-3 | IC50 |
8.9 μM
Compound: ONC201
|
Growth inhibition of human PC3 cells after 3 days by WST8 assay
Growth inhibition of human PC3 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| Raji | IC50 |
2.48 μM
Compound: ONC201
|
Antiproliferative activity against human Raji cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human Raji cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| RS4-11 | IC50 |
31.4 μM
Compound: ONC201
|
Growth inhibition of human RS4:11 cells after 3 days by WST8 assay
Growth inhibition of human RS4:11 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| SUM-159-PT | IC50 |
0.3 μM
Compound: 8; ONC201
|
Cytotoxicity against human SUM159 cells
Cytotoxicity against human SUM159 cells
|
[PMID: 37974956] |
| SUM-159-PT | IC50 |
1700 nM
Compound: 34; ONC201
|
Cytotoxicity against human SUM159PT cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Cytotoxicity against human SUM159PT cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 33656892] |
| SW480 | IC50 |
10.55 μM
Compound: ONC201
|
Antiproliferative activity against human SW480 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human SW480 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| SW-620 | IC50 |
9.17 μM
Compound: ONC201
|
Antiproliferative activity against human SW-620 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human SW-620 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| THP-1 | IC50 |
14.4 μM
Compound: ONC201
|
Growth inhibition of human THP1 cells after 3 days by WST8 assay
Growth inhibition of human THP1 cells after 3 days by WST8 assay
|
[PMID: 30783502] |
| U-251 | IC50 |
>20 μM
Compound: ONC201
|
Antiproliferative activity against human U-251 cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human U-251 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 35609303] |
| Z-138 | IC50 |
1 μM
Compound: 34; ONC201
|
Cytotoxicity against human Z138 cells assessed as cell growth inhibition at 5 uM measured after 72 hrs by spectrophotometry
Cytotoxicity against human Z138 cells assessed as cell growth inhibition at 5 uM measured after 72 hrs by spectrophotometry
|
[PMID: 33656892] |
| Z-138 | IC50 |
1 μM
Compound: 8; ONC201
|
Cytotoxicity against human Z138 cells
Cytotoxicity against human Z138 cells
|
[PMID: 37974956] |
Dordaviprone transcriptionally induces TRAIL in a p53-independent manner and crosses the blood-brain barrier[1].
Dordaviprone induces a sustained up-regulation of TRAIL in tumors and normal cells that may contribute to the demonstrable antitumor activity of Dordaviprone[1].
Dordaviprone inactivates kinases Akt and extracellular signal-regulated kinase (ERK), leading to the translocation of Foxo3a into the nucleus, where it binds to the TRAIL promoter to up-regulate gene transcription[1].
Dordaviprone is an efficacious antitumor therapeutic agent that acts on tumor cells and their micro-environment to enhance the concentrations of the endogenous tumor suppressor TRAIL[1].
Dordaviprone also causes a down-regulation of the total expression of ERK[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1616632-77-9
-
Appearance Solid
-
Molecular Weight 386.49
-
Formula C24H26N4O
-
Color White to yellow
-
SMILES
O=C1N(CC2=CC=CC=C2C)C3=NCCN3C4=C1CN(CC5=CC=CC=C5)CC4
-
Synonyms
TIC10; ONC-201
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
2019 May 13;35(5):721-737.e9. PMID: 31056398 -
Phytomedicine
Baizhu shaoyao decoction restores the intestinal barrier and brain-gut axis balance to alleviate diarrhea-predominant irritable bowel syndrome via FoxO1/FoxO3a. [Abstract]2024 Jan:122:155163. PMID: 37924689 -
NPJ Precis Oncol
Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]2025 Nov 21;9(1):373. PMID: 41272086 -
Cell Chem Biol
Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma. [Abstract]2022 Sep 15;29(9):1396-1408.e8. PMID: 35905743 -
Br J Cancer
Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. [Abstract]2023 Mar;128(7):1344-1359. PMID: 36717670 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
Biochem Biophys Res Commun
METTL16 deficiency attenuates apoptosis through translational control of extrinsic death receptor during nutrient deprivation. [Abstract]2024 May 14:708:149802. PMID: 38520913 -
-
-
Oncotarget
2018 Jan 10;9(15):12020-12034. PMID: 29552290
Dordaviprone purchased from MedChemExpress. Usage Cited in: Oncotarget. 2018 Jan 10;9(15):12020-12034. [Abstract]
WB detection of the total and phosphorylated ERK1/2, LC3B, p62, ATG5, ATG7 levels in the PC9/GR and HCC827/GR cells cultured in the four treatment conditions. 20 μM TIC10 treatment decreases the expression of LC3B-II, but increases the expression of p62 in both cells.
Solvent & Solubility
DMSO : 9.38 mg/mL (24.27 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
Floating and adherent cells are analyzed on a Coulter-Beckman Elite Epics cytometer. For surface TRAIL experiments, adherent cells are harvested by brief trypsinization, fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min, incubated with an anti-TRAIL antibody at 1:250 overnight, washed and incubated with anti-rabbit Alexa Fluor 488 for 30 min, and analyzed. Cells are gated on forward and side scatter to eliminate debris and dead cells from the analysis. Surface TRAIL data are expressed as median fluorescence intensity relative to that of control samples unless indicated otherwise. Surface DR5 is analyzed similarly with an antibody from Imgenex. For sub-G1content and cell cycle profile analysis, all cells are pelleted and ethanol-fixed, followed by staining with propidium iodide in the presence of RNase. Cell viability assays are carried out in 96-well black-walled clear-bottom plates with CellTiter-Glo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
For subcutaneous xenografts, 4- to 6-week-old female athymic nu/nu mice are inoculated with 1×106 cells (2.5×106 for T98G) of the indicated cell lines in each rear flank as a 200-μL suspension of 1:1 Matrigel (BD)/PBS. All subcutaneous tumors are allowed to establish for 1 to 4 weeks after injection until reaching a volume of ~125 mm3 before treatment initiation. All intraperitoneal and intravenous injections are given at a total volume of 200 μL. Oral formulations of Dordaviprone are administered by oral gavage and given as a 200 μL suspension containing 20% Cremophor EL, 10% DMSO, and 70% PBS. Tumors are monitored with digital calipers at indicated time points. All subcutaneous tumors are allowed to establish for 1-4 weeks post-injection until reaching a volume of ~125 mm3 before treatment initiation. Relief of tumor burden is monitored for 3 weeks after disappearance of the tumor and confirmed by visual inspection after euthanasia.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5874 mL | 12.9369 mL | 25.8739 mL | 64.6847 mL |
| 5 mM | 0.5175 mL | 2.5874 mL | 5.1748 mL | 12.9369 mL | |
| 10 mM | 0.2587 mL | 1.2937 mL | 2.5874 mL | 6.4685 mL | |
| 15 mM | 0.1725 mL | 0.8625 mL | 1.7249 mL | 4.3123 mL | |
| 20 mM | 0.1294 mL | 0.6468 mL | 1.2937 mL | 3.2342 mL |